Nail-Biting Time for Trials of COX-2 Drugs

3 December 2004

journal article
other
Published by American Association for the Advancement of Science (AAAS) in Science

Vol. 306 (5702), 1673-1675
https://doi.org/10.1126/science.306.5702.1673

Abstract

Preliminary studies suggest that the COX-2 inhibitor Celebrex may stem cancer and Alzheimer's disease, but testing these possibilities has just gotten tougher.

Cited by 25 articles